Shikonin inhibits myeloid differentiation protein 2 to prevent LPS-induced acute lung injury.

Yali ZhangTingting XuZheer PanXiangting GeChuchu SunChun LuHongjin ChenZhongxiang XiaoBing ZhangYuanrong DaiGuang Liang

Published in: British journal of pharmacology (2018)

Our studies have uncovered the mechanism underlying the biological activity of shikonin in ALI and suggest that the targeting of MD2 may prove to be beneficial as a treatment option for this condition.

Keyphrases

lps induced
inflammatory response
lipopolysaccharide induced
bone marrow
dendritic cells
acute myeloid leukemia
cancer therapy
molecular dynamics
immune response
combination therapy
case control
drug delivery
binding protein